Uric Acid Study in Healthy Male Volunteers

AstraZeneca

Status and phase: Completed; Phase 1

Conditions: Coronary Artery Disease; Gout

Treatments: Drug: Placebo to match AZD6140; Drug: AZD6140

Study type: Interventional

Funder types: Industry

Identifiers

NCT00738842

D5130C00050

Details and patient eligibility

About

This study is being conducted to examine the effect of AZD6140 on the levels of certain chemicals in subjects' blood and urine.

Enrollment: 24 patients

Sex: Male

Ages: 18 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Normal physical examination, vital signs, electrocardiogram (ECG) and laboratory values (unless the investigator considers an abnormality not to be clinically significant)
• Normal laboratory tests at screening
• Non-smoker (no cigarette/tobacco use for at least 6 months)

Exclusion criteria

• Personal or family history of gout, gouty arthritis, or renal stones

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

24 participants in 2 patient groups, including a placebo group

1

Experimental group

Treatment:

Drug: AZD6140

2

Placebo Comparator group

Treatment:

Drug: Placebo to match AZD6140